the future of glp 1 drugs What is pipeline for medications for obesity? 3 Ways GLP-1 Drugs Could

Workers with obesity have roughly 76% higher short-term disability rates than their normal-weight colleagues, meaning every employee who gains stable access to effective obesity treatment is statistically far less likely to go out on disability leave

In the short term, the brand name manufacturers will likely absorb much of the added expense rather than pass it on to patients, since the drugs are already at the high end of what insurers and patients can bear

Gronholt-Pedersen, J

[DOI] [PubMed] [Google Scholar] 724.Curtis K.S., Sved A.F., Verbalis J.G., Stricker E.M

Wegovy contains the active ingredient semaglutide, a GLP-1 agonist

The dataset will help study nonresponders (40% of Type 2 diabetes patients) and identify new biomarkers and drug targets